Research has determined that CAR-T cells and T cells are the main sources of GM-CSF in patients with CRS after CAR-T therapy, and elevated serum GM-CSF levels are positively correlated with the severity of CRS [57, 58]. This evidence concerns the gene CSF2 and congenital rubella syndrome.